We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

NRAS-Mutant Melanoma: Response to Chemotherapy

Christopher W. M. Soon, MD; Alain P. Algazi, MD; Edward N. Cha, MD, PhD; Emma M. Webb, MD; Adil I. Daud, MD
Arch Dermatol. 2011;147(5):626-627. doi:10.1001/archdermatol.2011.85.
Text Size: A A A
Published online


Middleton  MRGrob  JJAaronson  N  et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18 (1) 158- 166
Chapman  PBEinhorn  LHMeyers  ML  et al.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17 (9) 2745- 2751
Devitt  BALiu  WSalemi  R  et al.  Clinical outcome and pathologic features associated with NRAS mutation in cutaneous melanoma. J Clin Oncol 2010;28 ((suppl, abstr 8500)) 15s
Davies  MAStemke-Hale  KLin  E  et al.  Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 2009;15 (24) 7538- 7546
PubMed Link to Article[[XSLOpenURL/10.1158/1078-0432.CCR-09-1985]]
Cheng  JQLindsley  CWCheng  GZYang  HNicosia  SV The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005;24 (50) 7482- 7492
PubMed Link to Article[[XSLOpenURL/10.1038/sj.onc.1209088]]

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

Care at the Close of Life: Evidence and Experience
The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?"

Care at the Close of Life: Evidence and Experience
Chemotherapy and Hormonal Therapy